Amarin Corp Plc (AMRN)

[sts66]

I read the NICE page to say they're taking public comments until April 16 - I don't think AMRN gets another bite at the apple to try to convince NICE of V's benefits - I'd have to go back and read the first review's text, but IIRC they were even harsher on V as far as possible MO effects on R-IT results - I don't remember seeing 7%-13% before. The 2nd review release was after AMRN reps met with NICE again, and they failed to change their minds. Don't think there's anything anyone can do at this point, but if you think flooding their website with comments disagreeing about their conclusions will help go for it - though it would be better if potential Brit patients were the ones complaining rather than US investors.

What I really don't understand with the UK's position is something like a dozen EU health organizations have blessed V for R-IT patients - UK is saying "you guys have been hoodwinked, we know better"? I really think this is just about money, plain and simple - UK knows it will cost their healthcare system > $26M/yr if they cover V, and that's sort of their breaking point - they actually ration drugs over their by cost/benefit, like only a certain number of patients per year can get Hep C cured by drugs. I don't know how the real doctors on that decision team sleep at night knowing many people will die because they couldn't afford to pay for V out of pocket.